For healthcare professionals only.
X
REVLIMID significantly extended OS to more than
9 years post auto-HSCT—a >2-year improvement
compared with no maintenance1*
Auto-HSCT=autologous hematopoietic stem cell transplantation;
MM=multiple myeloma; OS=overall survival.
A Foundation of Therapy in MM1
11/18 INT-REV180024
EU Summary of Product Characteristics
Study Design and References
X
*Median OS was 111.0
months vs 84.2 months with
no maintenance (HR=0.61;
95% CI, 0.46-0.81; P<0.001).
Reference:
1. REVLIMID [Summary of
Product Characteristics].
Utrecht, Netherlands,
Celgene Europe B.V.; 2018.